Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT05003245 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Age Related Macular Degeneration

Interventions

DRUG: HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
DRUG: Lucentis

Sponsor

Shanghai Henlius Biotech